Last reviewed · How we verify
Catabolic Process — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Oxandrin | OXANDROLONE | Crealta Pharms Llc | oxandrolone | Androgen receptor | 1964-01-01 | |
| Oxandrin | Oxandrin | Par Pharmaceutical, Inc. | Androgen receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Catabolic Process
- Crealta Pharms Llc · 1 drug in Catabolic Process
- Par Pharmaceutical, Inc. · 1 drug in Catabolic Process
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Catabolic Process:
- Catabolic Process treatment updates — RSS
- Catabolic Process treatment updates — Atom
- Catabolic Process treatment updates — JSON
Cite this brief
Drug Landscape (2026). Catabolic Process — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/catabolic-process. Accessed 2026-06-10.
Related
- Catabolic Process full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing